Alzheimer's subtypes reveal new drug targets

The Alzheimer's landscape is evolving, with recent advancements offering new hope and demanding a reevaluation of treatment and research strategies. The Alzheimer's Association International Conference (AAIC) 2026, held in London from July 12-15, saw experts discuss significant developments, including the emergence of disease-modifying therapies and blood-based biomarker tests. These innovations are poised to revolutionize Alzheimer's care.

Research presented at AAIC 2026 suggests Alzheimer's may not be a single disease but could encompass at least five distinct subtypes, each driven by different biological factors. This groundbreaking theory, proposed by Betty Tijms, could explain why certain therapies have failed in clinical trials and offers new avenues for drug developers beyond traditional amyloid and tau targets. The findings underscore the potential need for subtype-specific biomarkers and therapeutics.

Biomarkers, particularly blood-based tests for indicators like p-tau217, are increasingly recognized as the next frontier for accessible Alzheimer's research and care. However, concerns about the accessibility of these diagnostic tools, including spinal fluid and plasma tests, were raised, especially in regions like Latin America where public coverage is lacking. Experts agreed that global healthcare systems need significant bolstering to meet the growing demand for testing infrastructure, particularly in Europe.

A critical focus at AAIC 2026 was the imperative for diversity and inclusion in research. Experts warned that a lack of diversity compromises the ethics, validity, and real-world applicability of studies. Strategies discussed included fostering community involvement in co-development and considering specific cultural needs in research design. Additionally, the conference explored optimizing treatment through combination therapies and early intervention, with companies investigating anti-amyloid treatments in preclinical settings.

Early diagnosis remains paramount to unlocking the full benefits of new therapeutic approaches. As disease-modifying therapies become more integrated, the emphasis is on new medicines, optimized use of existing tools, and mitigating neuroinflammation. Companies are exploring anti-amyloid treatments in earlier disease stages, highlighting the potential of preclinical interventions to improve long-term patient outcomes.